Insider Surge: Douglas & Execs Buy 10k Inhibrx Options, Signaling 25% Upside

Insider Buying Signals: Douglas Locks in a New Batch of Options

On June 3, 2026, former director Forsyth Douglas executed a 10,000‑share block of stock options, filing a Form 4/A that identifies the transaction as a derivative rather than a direct purchase of common equity. The options were granted on the same day and will be fully exercisable on June 3, 2027. Although the options are currently at‑no‑cost, the grant price is expected to be near the prevailing market price of $109.35, which positions Douglas to realize a potential upside of roughly 25 % should the share price rise before vesting.

The action signals that insiders believe Inhibrx is undervalued relative to its 52‑week high of $155.29 and that the company’s growth trajectory remains robust.

Broader Insider Activity Signals Momentum

Within the same filing window, three other senior executives—Vuori Kristiina MD, Kimberly Manhard, and Jon Faiz Kayyem—each acquired 10,000 options. This concentration of option purchases on a single date is atypical and suggests a coordinated confidence in Inhibrx’s near‑term prospects. While options do not represent immediate cash flow, they align the interests of executives with those of shareholders, as the value of the options is directly tied to the performance of the share price.

The timing of these purchases coincides with a modest 0.07 % weekly price gain and a 7.76 % monthly increase, indicating that the market has already begun to react to positive catalysts, potentially related to clinical pipeline developments or forthcoming partnership announcements that have yet to be publicly disclosed.

Implications for Investors

1. Alignment of Interests – The simultaneous option purchases by multiple executives reinforce a narrative that the leadership team is optimistic about the company’s valuation. Investors may view this as a signal that insiders expect a rally in the coming months.
2. Potential Share‑Price Upside – If Inhibrx’s stock continues its upward trajectory, the options will likely become valuable before they vest. This can create a positive feedback loop, where insider confidence fuels market enthusiasm, driving the price higher.
3. Risk of Lock‑in Periods – Options usually vest over a multi‑year schedule, so the immediate impact on liquidity is limited. However, if insiders exercise early, it could add pressure on the price if the supply increases.

Forsyth Douglas: A Profile of Consistent Commitment

Douglas has a long history of purchasing stock options and shares in Inhibrx, dating back to May 2025. Over the past 18 months he has acquired:

This pattern demonstrates a steady accumulation of equity without significant divestitures, indicating a belief in long‑term value creation rather than short‑term speculation. Unlike some insiders who mix sales and purchases, Douglas’s activity is largely buy‑heavy, suggesting that he expects the company’s fundamentals to improve over the next two to three years.

Conclusion

The recent Form 4/A filings, coupled with a broader wave of option purchases by senior executives, paint a picture of an insider group that is bullish on Inhibrx Biosciences. While options do not immediately alter share supply, they signal confidence and set the stage for potential future upside. For investors, the key takeaway is that the leadership’s recent moves could presage a period of accelerated growth, but they should remain vigilant for any shifts in the company’s clinical pipeline or regulatory environment that could alter this optimistic outlook.